Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
about
Mepolizumab versus placebo for asthmaA review of omalizumab for the management of severe asthmaAsthma-related comorbidities.Omalizumab in children.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.Omalizumab, an anti-immunoglobulin E antibody: state of the art.Optimal duration of allergic rhinitis clinical trials.Omalizumab in the treatment of allergic respiratory disease.Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to omalizumab treatmentNovel therapeutic interventions for allergic rhinitis.The impact of comorbid atopic disease on asthma: clinical expression and treatment.New treatment options in allergic rhinitis: patient considerations and the role of ciclesonideAnti-immunoglobulin e therapyAnti-IgE in allergic asthma and rhinitis: an update.Investigational drugs for allergic rhinitis.Omalizumab: Anti-IgE therapy in allergy.Safety of omalizumab in asthma.Biologic modulators in allergic and autoinflammatory diseases.Immune modulation for treatment of allergic disease.Emerging drugs for perennial allergic rhinitis.Anti-IgE--emerging opportunities for Omalizumab.Omalizumab for treatment of allergic rhinitis.Pediatric allergic rhinitis and asthma: can the march be halted?Pharmacotherapy of allergic rhinitis: current options and future perspectives.Investigational drugs for the treatment of allergic rhinitis.Pharmacotherapy for allergic rhinitis.Developing therapies for peanut allergy.Focusing the mechanism of action to dissect the different treatments of respiratory allergy.From IgE to clinical trials of allergic rhinitis.Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments.Emerging drugs for the treatment of perennial allergic rhinitis.Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis.From IgE to Omalizumab.Update on oral immunotherapy for egg allergy.Endotype-driven treatment in chronic upper airway diseases.Current and future applications of the anti-IgE antibody omalizumab.Severe asthma and the omalizumab option.Anti-IgE Treatment for Disorders Other Than Asthma.Mometasone furoate monohydrate nasal spray for the treatment of nasal congestion in allergic rhinitis.An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases.
P2860
Q24186306-6F0655D2-CB85-4C21-B389-ADD2EECD5B61Q26741315-2441445A-C721-469B-AA9D-9908CA00AA99Q34195201-6BF9F7C6-906D-4DB8-9926-DABEF922F4AFQ34604574-58C93111-9A6C-41FC-BBC6-97D31A9A22E0Q34623856-3D165F99-E96D-48AA-BCDA-7EFE5B4782C0Q35095218-3FC0FCC8-44ED-4B3D-AA2E-84D8C0A64273Q36281063-E8A50046-984D-4897-903B-15CE48A52ED7Q36414178-12E3D7AA-8D0F-490C-885E-4F5AFD09CA58Q36577451-60F27D49-4F4B-4E5D-A4F5-5D02C05DEB10Q36654345-A38C3FA4-80FD-4E1D-AD84-3F807F4BA053Q36799761-1CD7DA61-CF53-4996-8EBD-07C9A7D6437BQ36823610-E763EAAD-D277-4B2E-90F4-8C5C91554326Q36834564-83DFAE43-8E85-462D-B1E9-230BD1E5DE8CQ36981688-3B63A249-186B-4436-89EA-FEB8BB3AB287Q37650382-5CB18047-CC19-4798-8F21-104F22866044Q37829671-261F8CAB-97C7-43B8-81C3-F75D409EA41EQ37852717-FFA915D6-9816-489A-B115-4817C947B1D8Q37887422-5CEB1457-58BB-4341-8C63-26DADC7E69C3Q37891140-69ADD081-7952-4094-A046-6F6523A92D90Q38062942-C72B0698-68B6-4045-B259-B5AEC67EB201Q38091754-A902D14D-BB5D-47B3-B753-8CB510303D3BQ38101972-4C516C91-E86B-4E6E-87A5-4E2A587330FAQ38129766-CEF22DD1-BAFA-4BFF-97A1-62810E6EACA4Q38161991-393507DC-D34C-4618-800B-BCB2EB60892EQ38202695-3604BE48-F229-4AC7-A6DD-98AC43EC3646Q38245581-48B6F8E9-DB53-427C-976B-27419B186C99Q38296706-23224C6C-84C1-4FDD-9820-6B87AC1E2FFAQ38542919-D634CA90-648E-49F3-B6B2-0FEBBBF9D2EDQ38584348-49990723-F579-4E9C-A638-E243FC64268AQ38602604-269E64ED-B132-4A51-914C-DA4651626769Q38687640-51D8C37C-06C2-48F2-9D07-A316A986FBA8Q38708066-A2E0876D-CD9E-419F-92CF-9F7B6DD64B2AQ38793428-070B3860-9443-42CE-9DDA-6F18D18AD9BFQ39428534-0D7CD07B-7837-463D-81FC-9C347C5E7763Q39434071-B6CBDA81-7568-4871-92AB-2A3C83A6519DQ40119246-8C2DDB2E-368B-4371-A192-22266359F2ECQ40740336-FC86EBB0-39BF-40D4-9458-37449BEE4305Q42091038-B4474FDE-7440-4C55-8C7E-A2916AD497D3Q43061697-97C0EC19-B90B-4454-9BEC-0ECEB4B286E0Q47146658-362AF142-181C-4FFC-8D7D-610A4E02F897
P2860
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Omalizumab, an anti-IgE antibo ...... h perennial allergic rhinitis.
@en
Omalizumab, an anti-IgE antibo ...... h perennial allergic rhinitis.
@nl
type
label
Omalizumab, an anti-IgE antibo ...... h perennial allergic rhinitis.
@en
Omalizumab, an anti-IgE antibo ...... h perennial allergic rhinitis.
@nl
prefLabel
Omalizumab, an anti-IgE antibo ...... h perennial allergic rhinitis.
@en
Omalizumab, an anti-IgE antibo ...... h perennial allergic rhinitis.
@nl
P2093
P1476
Omalizumab, an anti-IgE antibo ...... h perennial allergic rhinitis.
@en
P2093
Angel Fowler-Taylor
Henry Shen
Howard Fox
Ita Tripathy
Paul Chervinsky
Robert Townley
Simon Hedgecock
Thomas Casale
P304
P356
10.1016/S1081-1206(10)62171-0
P577
2003-08-01T00:00:00Z